Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation at its ...

Pfizer's top-selling product last year was Eliquis, which it co-markets with Bristol Myers Squibb. The blood thinner ...

Pfizer’s (PFE) stock has fallen ill since the COVID-19 pandemic waned, and it is still experiencing some aftereffects. The ...

Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...

Institutional Shareholder Services has recommended Pfizer investors reject a proposal on executive compensation due to ...

Pfizer and Flagship Pioneering have entered into an agreement aimed at discovering potential selective inhibitors for ...

Pfizer and Flagship Pioneering are turning to autoimmune disease as the sixth plank of their multibillion-dollar, 10-program ...

In the closing of the recent trading day, Pfizer (PFE) stood at $24.70, denoting a +0.65% change from the preceding trading day.

Pfizer delayed the announcement of its COVID-19 vaccine until after the 2020 election when it thought Donald Trump was ...

The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...

The report said GSK’s former head of vaccine development, Philip Dormitzer, who joined the company after working at ...

President Trump has claimed in the past Pfizer sat on positive vaccine data, but no evidence has supported the accusation.